Osteoporosis Treatment Options

First-Line Treatment: Bisphosphonates

For most patients with osteoporosis, oral bisphosphonates (alendronate or risedronate) or intravenous zoledronic acid should be prescribed as initial therapy, with generic formulations strongly preferred due to equivalent efficacy at significantly lower cost. 1, 2

Specific Bisphosphonate Agents and Dosing:

Alendronate: 70 mg once weekly or 10 mg daily 2, 3
Risedronate: 35 mg once weekly, 5 mg daily, 75 mg on two consecutive days per month, or 150 mg monthly 2
Zoledronic acid: 5 mg IV annually 2

Mechanism and Efficacy:

Bisphosphonates bind to bone hydroxyapatite and inhibit osteoclast activity, reducing bone resorption without directly affecting bone formation 3
They reduce hip, vertebral, and nonvertebral fractures with high-certainty evidence 1, 2
Biochemical markers of bone resorption decrease by 50-70% within 1-6 months, with bone formation markers decreasing by approximately 50% 3

Treatment Duration and Monitoring:

Treat for 5 years initially, then reassess fracture risk to determine whether to continue or take a drug holiday 1, 2
Do not perform bone density monitoring during the 5-year treatment period 1
Serum calcium decreases approximately 2% and phosphate 4-6% during treatment, which is expected and asymptomatic 3

Administration Considerations:

Must be taken on an empty stomach with plain water, remaining upright for at least 30 minutes to minimize esophageal adverse events 3
Upper GI adverse events (abdominal pain, nausea, dyspepsia, acid regurgitation) are the most common side effects, though large trials show no statistically significant difference from placebo 4

Second-Line Treatment: Denosumab

Denosumab 60 mg subcutaneously every 6 months is reserved for patients with contraindications to bisphosphonates or who experience adverse effects from bisphosphonates. 1, 2

Evidence Quality:

Moderate-certainty evidence for postmenopausal women 1, 2
Low-certainty evidence for men 1, 2

Critical Safety Warning:

Denosumab discontinuation causes rebound bone loss and multiple vertebral fractures—patients MUST transition to bisphosphonate therapy after stopping denosumab 1, 2, 5
This is a high-certainty finding and represents a major clinical pitfall to avoid 1

Additional Serious Risks:

Severe jaw bone problems (osteonecrosis of the jaw)—dental examination required before starting treatment 5
Unusual thigh bone fractures 5
Serious infections (skin, abdomen, bladder, ear, endocarditis) due to immune system effects 5
Severe allergic reactions including hypotension, throat tightness, and rash 5
Skin problems (dermatitis, rash, eczema) 5

Contraindications:

Low blood calcium levels 5
Pregnancy or planned pregnancy (use effective contraception during treatment and for 5 months after last dose) 5
Allergy to denosumab 5

Very High-Risk Patients: Anabolic Agents First

For patients at very high risk for fracture, anabolic agents (teriparatide or romosozumab) should be initiated BEFORE bisphosphonates, followed by mandatory transition to bisphosphonates or denosumab to maintain bone gains. 1, 6

Defining Very High Risk:

Age >74 years 1, 6, 2
Recent fracture within 12 months 1, 2
Multiple prior osteoporotic fractures 1, 6, 2
T-score ≤-3.0 1, 6, 2
Fractures despite ongoing bisphosphonate therapy 1, 2
High FRAX scores (≥20% for major osteoporotic fracture or ≥3% for hip fracture) 1, 6

Teriparatide:

Dosing: 20 mcg subcutaneously daily for up to 24 months 2, 7
Efficacy: Reduces vertebral fractures by 69 per 1000 patients and any clinical fractures by 27 per 1000 patients (high-certainty evidence) 1, 6, 2
Indications: Postmenopausal women at high risk for fracture, men with primary or hypogonadal osteoporosis at high risk, and glucocorticoid-induced osteoporosis 7
Mechanism: Stimulates bone formation without directly inhibiting bone resorption 7

Romosozumab:

Dosing: Limited to 12 monthly doses due to waning anabolic effect 1, 2
Conditionally recommended for very high-risk postmenopausal women with moderate-certainty evidence 1, 6

Mandatory Sequential Therapy:

After completing anabolic therapy, patients MUST transition to bisphosphonate or denosumab to maintain bone density gains and prevent rapid bone loss 2
This is high-certainty evidence and failure to transition will result in loss of therapeutic benefit 2

Essential Adjunctive Measures for ALL Patients

Every patient receiving osteoporosis treatment requires the following non-pharmacologic interventions: 1, 6

Calcium: 1000-1200 mg daily 1, 6, 2
Vitamin D: 800-1000 IU daily, with serum level maintained at ≥20 ng/mL 1, 6
Weight-bearing and muscle resistance exercises 1, 6
Balance exercises and fall prevention counseling 1, 6
Smoking cessation 1, 6
Alcohol reduction 1, 6

Agents NOT Recommended

The American College of Physicians strongly recommends AGAINST using estrogen therapy, estrogen plus progestogen, or raloxifene for osteoporosis treatment due to unfavorable risk-benefit profiles. 2

These agents carry risks of cardiovascular events, thromboembolic complications, and stroke 2
This is a strong recommendation against use with moderate-quality evidence 2

Treatment Indications

Treatment should be initiated for: 1

T-score ≤-2.5 1
T-score between -1.0 and -2.5 with 10-year FRAX risk of major osteoporotic fracture ≥20% or hip fracture ≥3% 1
Low-trauma fracture, even if DEXA does not indicate osteoporosis 1

Common Pitfalls to Avoid

Never stop denosumab without transitioning to bisphosphonate—this causes rebound vertebral fractures 1, 2, 5
Never use anabolic agents without planning sequential antiresorptive therapy—bone gains will be lost 2
Never prescribe bisphosphonates without proper administration instructions—esophageal complications can occur 3, 4
Never forget calcium and vitamin D supplementation—pharmacologic therapy alone is insufficient 1, 6, 2
Never use estrogen or raloxifene as first-line therapy—unfavorable risk-benefit profile 2

What are the treatment options for osteoporosis?

Help us tailor your experience